Clinical Trend of the Week (February 17-23): Follicular Lymphoma
The health of a high-profile executive and a potential treatment resulted in this week's top search term. Nicola Mendelsohn—Facebook's vice president for Europe, the Middle East, and Africa—recently revealed that she has follicular lymphoma. The condition is currently incurable, although a large number of patients live for many years with appropriate treatments. Available therapies may be expanding as well, with Verastem having just submitted a drug application to the US Food and Drug Administration for duvelisib, a first-in-class oral dual phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma inhibitor. The company is seeking approval for use in the treatment of relapsed or refractory follicular lymphoma and in those with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic leukemia. Hopefully, persons like Nicola Mendelsohn who are living with follicular lymphoma will soon have a new, effective means to combat this condition.
For more information on follicular lymphoma, read here.
Medscape © 2018
Cite this: Ryan Syrek. Trending Clinical Topics for February 2018 - Medscape - Mar 02, 2018.